Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA) Following FDA Approval of mRNA Flu Vaccine
August 6, 2026 8:42 AM EDTPiper Sandler analyst Edward Tenthoff reiterated an Overweight rating and a $77.00 price target on Moderna (NASDAQ: MRNA) following the FDA's approval of the company's mRNA flu vaccine.
The analyst commented, "The FDA granted approval for mFLUSIVA (mRNA-1010) to prevent seasonal influenza infection... More
